Study identifier:D1448C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Multi-centre,Double-blind,Randomised-Withdrawal,Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine SR as Monotherapy in the Maintenance Treatment of Patients with GAD Following an Open-Label Stabilisation Period
Anxiety Disorders
Phase 3
No
Quetiapine SR
All
575
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Location
Location
Owensboro, KY, United States
Location
Brisbane, QLD, Australia
Location
WEST BURLEIGH, QLD, Australia
Location
Everton Park, QLD, Australia
Location
Malvern, VIC, Australia
Location
Edmonton, AB, Canada
Location
Bathurst, NB, Canada
Location
Hamilton, ON, Canada
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.